Publication | Open Access
Metabolic Syndrome and Risk of Coronary, Cerebral, and Peripheral Vascular Disease in a Large Dutch Population With Familial Hypercholesterolemia
24
Citations
25
References
2006
Year
HypertensionMetabolic DisorderCardiometabolic RiskGenetic EpidemiologyHyperlipidemiaObesityMetabolic SyndromeLarge Dutch PopulationNeurologyPublic HealthCardiovascular Disease PathogenesisAtherosclerosisDyslipidemiaLipid DisorderMedicineInherited Metabolic DiseasePeripheral VascularEpidemiologyCoronary Heart DiseaseMetabolic ComplicationFamilial HypercholesterolemiaCardiovascular DiseaseMetabolic DiseaseDiabetesLipid DisordersGlobal HealthInflammatory Vascular DiseaseCardiovascular Risk FactorsStrokeCardiovascular Genetics
Various studies (1–16) in recent years have reported that the metabolic syndrome is associated with an increase in cardiovascular disease (CVD). However, there is still an uncertainty about the clinical importance and consequences of the metabolic syndrome (17). There is paucity of data looking at the effect of metabolic syndrome, specifically on cerebrovascular (CeVD) (9,12,18,19) and peripheral vascular (PVD) disease. Heterozygous familial hypercholesterolemia (FH) is a common hereditary disorder of lipoprotein metabolism (prevalence 1:400). The disorder is caused by mutations in the LDL receptor gene. The objective of our study was to assess if there was an additional risk associated with the presence of metabolic syndrome for coronary disease, CeVD, and PVD in this high-risk population, which included patients inducted from 27 clinics around the Netherlands. The database for the current study is the molecular diagnostic center for nationwide FH screening in the Netherlands, located at the Academic Medical Centre, University of Amsterdam. A total of 2,400 patients fulfilled the diagnostic criteria for FH and were included in the study. The inclusion and exclusion criteria for participation in the study and details of the data collection are outlined and previously discussed in detail (20–22). The ethics institutional review board of each participating hospital approved …
| Year | Citations | |
|---|---|---|
Page 1
Page 1